The combination of bevacizumab/Avastin and erlotinib/Tarceva is relevant for the treatment of metastatic renal cell carcinoma: the role of a synonymous mutation of the EGFR receptor

Metastatic clear cell renal cell carcinomas (mRCC) over-express the vascular endothelial growth factor (VEGF). Hence, the anti-VEGF antibody bevacizumab/Avastin (BVZ) combined with interferon alpha (IFN) was approved for the treatment of mRCC. However, approval was lost in July 2016 due to the absen...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Theranostics
Main Authors: Grépin, Renaud, Guyot, Mélanie, Dumond, Aurore, Durivault, Jérôme, Ambrosetti, Damien, Roussel, Jean-François, Dupré, Florence, Quintens, Hervé, Pagès, Gilles
Formato: Artigo
Idioma:Inglês
Publicado em: Ivyspring International Publisher 2020
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6956821/
https://ncbi.nlm.nih.gov/pubmed/31938054
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.38346
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados